Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma
Top Cited Papers
Open Access
- 6 April 2018
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 5, 49
- https://doi.org/10.3389/fmed.2018.00049
Abstract
Improved understanding of the contribution of eosinophils to various chronic inflammatory conditions, most notably allergic asthma, has encouraged development of monoclonal antibodies specifically targeting mediators and surface receptors involved in eosinophil expansion and activation. The pivotal role of interleukin-5 (IL-5) in eosinophil biology, its high specificity for this leucocyte subset, and its involvement in the majority of eosinophilic conditions make it a very enticing target for treatment of eosinophil-mediated disorders. Two types of antibodies have been developed to target eosinophils: antibodies against IL-5 (mepolizumab and reslizumab), and an antibody against the IL-5-receptor-alpha-chain (IL-5Rα) (benralizumab). Both types of antibodies prevent IL-5 from engaging its receptor and in addition, anti-IL-5Rα antibodies induce target cell lysis. They have been shown to reduce circulating eosinophil counts rapidly in humans with various disorders. Herein, a brief overview of the role of IL-5 in eosinophil biology will be presented, followed by a description of the development and characteristics of antibodies targeting IL-5 or its receptor. Results of clinical trials evaluating the efficacy and safety of these new antibodies in diseases (other than eosinophilic asthma) with prominent tissue eosinophilia are reviewed, followed by safety considerations and potential future applications.Keywords
Funding Information
- Fonds De La Recherche Scientifique - FNRS (F 5/4/150/5)
This publication has 117 references indexed in Scilit:
- Power of Rare Diseases: Found in TranslationScience Translational Medicine, 2013
- IL-5 receptor α levels in patients with marked eosinophilia or mastocytosisJournal of Allergy and Clinical Immunology, 2011
- Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndromeJournal of Allergy and Clinical Immunology, 2010
- Treatment of a Case of Pediatric Hypereosinophilic Syndrome with Anti-Interleukin-5The Journal of Pediatrics, 2009
- Dissociation Between Symptoms and Histological Severity in Pediatric Eosinophilic EsophagitisJournal of Pediatric Gastroenterology and Nutrition, 2009
- Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levelsJournal of Allergy and Clinical Immunology, 2008
- Angiolymphoid hyperplasia with eosinophilia treated with anti-interleukin-5 antibody (mepolizumab)British Journal of Dermatology, 2004
- The trials and tribulations of IL-5, eosinophils, and allergic asthmaJournal of Allergy and Clinical Immunology, 2001
- IL-5-Deficient Mice Have a Developmental Defect in CD5+ B-1 Cells and Lack Eosinophilia but Have Normal Antibody and Cytotoxic T Cell ResponsesImmunity, 1996
- Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model.The Journal of Experimental Medicine, 1996